- A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2016 Academic Article GET IT
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 27
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Breast cancer research : BCR.
Times cited: 32
- High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leukemia & lymphoma. 2012 Academic Article GET IT
- Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2012 Academic Article GET IT
- Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer. 2011 Academic Article GET IT
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Expert review of anticancer therapy.
Times cited: 131
Adjuvant taxanes: more to the story.
Clinical breast cancer.
Times cited: 9
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Investigational new drugs.
Times cited: 24
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
Molecular cancer therapeutics.
Times cited: 30